Tivozanib (trade name Fotivda) is an oral VEGF receptor tyrosine kinase inhibitor. It has completed a Phase 3 investigation for the treatment of first line (treatment naive) patients with renal cell carcinoma.[1] The results from this first line study did not lead to US FDA approval, but tivozanib was approved by the European Medicines Agency (EMA) in August 2017.[2]